FDA Warns German Device Firm Over Lack of Procedures

The GMP Letter
A A
A four-day FDA inspection of Curasan’s manufacturing facility in Frankfurt, Germany revealed a lack of manufacturing and adverse event reporting procedures.

To View This Article:

Login

Subscribe To The GMP Letter